Aromatase (CYP19) Polymorphism Between AI-responsive and AI-resistant Breast Cancer in Korea

Status

Suspended

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01137136

Acronym

CYP19

Enrollment

300

Registered

2010-06-04

Start date

2010-06-30

Completion date

2015-12-31

Last updated

2014-04-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Aromatase Inhibitor, CYP19, Polymorphism

Brief summary

Aromatase(CYP19)inhibitor is one of the major antihormonal drug for breast cancer in postmenopausal women. The variation of CYP19 may affect the effect of aromatase inhibitor. However, the incidence of variation of CYP19 in Korea has not known. Therefore, the investigators want to know the incidence of variation of CYP19 and to assess the effect of these variations of CYP19 to aromatase inhibitor users.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

FEMALE

Age

No minimum to 80 Years

Healthy volunteers

Yes

Inclusion criteria

* hormone receptor positiveBreast cancer patient * postmenopausal women * first user of aromatase inhibitor

Exclusion criteria

* premenopausal * The patient who take the other antihormonal therapy * osteoporosis patients

Design outcomes

Primary

Measure	Time frame
The prevalence of CYP19 polymorphism	12. 31. 2011

Secondary

Measure	Time frame
The effect of CYP19 polymorphism to the prognosis of AI user	12. 31. 2016

Countries

South Korea

Outcome results